<DOC>
	<DOCNO>NCT00845065</DOCNO>
	<brief_summary>Based previous experience peginterferon alfa-2b/ribavirin combination boceprevir , combination peginterferon alfa- 2a/ribavirin boceprevir expect safe well tolerate . Given wide utilization peginterferons clear benefit addition boceprevir peginterferon alfa-2b/ribavirin , important demonstrate safety efficacy boceprevir combination peginterferon alfa-2a/ribavirin .</brief_summary>
	<brief_title>Boceprevir Combination With Peginterferon Alfa-2a Ribavirin Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin ( Study P05685AM2 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subjects must qualify regimen define peginterferon alfa2a/ribavirin peginterferon alfa2b/ribavirin minimum 12 week . During qualify regimen , subject must either : A documented undetectable Hepatitis C VirusRibonucleic Acid ( HCVRNA ) within 30 day endoftreatment subsequent detectable HCVRNA followup OR A documented decline HCVRNA &gt; =2 log10 12 week treatment . Subject must previously document chronic hepatitis C genotype 1 infection . Subject must liver biopsy histology consistent chronic hepatitis C infection etiology . Subjects bridge fibrosis cirrhosis must ultrasound within 6 month finding suspicious hepatocellular carcinoma ( HCC ) . Subject must &gt; =18 year age . Subject must weigh 40 kg 125 kg . Subject subject 's partner ( ) must agree use acceptable method contraception . Subjects must willing give write informed consent . Subject exclude entry ANY criterion list meet : Subjects know coinfected human immunodeficiency virus ( HIV ) hepatitis B virus ( hepatitis B surface antigen [ HBsAg ] positive ) and/or demonstrate sign symptom consistent coinfection . Subjects require discontinuation previous interferon ribavirin regimen adverse event consider investigator possibly probably related ribavirin and/or interferon . Treatment ribavirin within 90 day interferon alfa within 1 month Screening . Treatment hepatitis C investigational medication . Prior treatment herbal remedy know hepatotoxicity exclusionary . Treatment investigational drug within 30 day randomization visit study . Participation clinical trial within 30 day randomization intention participate another clinical trial participation study . Evidence decompensated liver disease . Diabetic and/or hypertensive subject clinically significant ocular examination finding . Preexisting psychiatric condition ( ) . Clinical diagnosis substance abuse . Any known preexisting medical condition could interfere subject 's participation completion study . Evidence active suspect malignancy , history malignancy , within last 5 year ( except adequately treat carcinoma situ basal cell carcinoma skin ) . Subjects pregnant nursing . Subjects intend become pregnant study period . Male subject partner intend become pregnant study period . Any condition , opinion physician , would make subject unsuitable enrollment could interfere subject participate completing study . Subjects part site personnel directly involve study . Subjects family member investigational study staff . Subjects lifethreatening serious adverse event ( SAE ) screen period . Subjects history pancreatitis , except one episode clearly secondary gallstone . Laboratory Hematologic , biochemical , serologic criterion ( growth factor may use achieve study entry requirement ) : Hemoglobin ( Hgb ) &lt; 12 g/dL female &lt; 13 g/dL male Neutrophils &lt; 1500/mm3 ( black : &lt; 1200/mm3 ) Platelets &lt; 100,000/mm3 Direct bilirubin &gt; 1.5 x upper limit normal ( ULN ) laboratory reference range . Total bilirubin &gt; 1.6 mg/dL unless subject history Gilbert 's disease . If Gilbert 's disease propose etiology , must document subject 's chart . Serum albumin &lt; low limit normal ( LLN ) laboratory reference range . Thyroidstimulating hormone ( TSH ) &gt; 1.2 x ULN &lt; 0.8 x LLN laboratory reference range . Serum creatinine &gt; ULN laboratory reference range . Serum glucose : For subject previously diagnose diabetes mellitus : &gt; =140 mg/dL ( nonfasting ) unless hemoglobin A1c subtype ( HbA1c ) &lt; =7 % OR &gt; =100 mg/dL ( fast ) unless HbA1c &lt; =7 % . For subject previously diagnose diabetes mellitus : HbA1c &gt; 8.5 % . Prothrombin time/partial thromboplastin time ( PT/PTT ) value &gt; 10 % laboratory reference range . Antinuclear antibody ( ANA ) &gt; 1:320 . Alpha fetoprotein ( AFP ) : AFP &gt; 100 ng/mL OR AFP 50 100 ng/mL require liver ultrasound subject find suspicious HCC exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>